ArticleBritish journal of cancer2017

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Eric Angevin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.